| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1734 | 2011 |
| Lenalidomide after stem-cell transplantation for multiple myeloma PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ... New England Journal of Medicine 366 (19), 1770-1781, 2012 | 1353 | 2012 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1120 | 2014 |
| The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, ... Blood, The Journal of the American Society of Hematology 116 (13), 2286-2294, 2010 | 955 | 2010 |
| CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma J Chu, Y Deng, DM Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, ... Leukemia 28 (4), 917-927, 2014 | 481 | 2014 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 458 | 2014 |
| Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC SM Collins, CE Bakan, GD Swartzel, CC Hofmeister, YA Efebera, H Kwon, ... Cancer Immunology, Immunotherapy 62, 1841-1849, 2013 | 355 | 2013 |
| Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche CC Hofmeister, J Zhang, KL Knight, P Le, PJ Stiff Bone marrow transplantation 39 (1), 11-23, 2007 | 320 | 2007 |
| A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma DM Benson Jr, CC Hofmeister, S Padmanabhan, A Suvannasankha, ... Blood, The Journal of the American Society of Hematology 120 (22), 4324-4333, 2012 | 266 | 2012 |
| IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect DM Benson Jr, CE Bakan, S Zhang, SM Collins, J Liang, S Srivastava, ... Blood, The Journal of the American Society of Hematology 118 (24), 6387-6391, 2011 | 233 | 2011 |
| Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 15 (2), 230-269, 2017 | 230 | 2017 |
| Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, ... Journal of Clinical Oncology 38 (17), 1928-1937, 2020 | 212 | 2020 |
| A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma DM Benson Jr, AD Cohen, S Jagannath, NC Munshi, G Spitzer, ... Clinical Cancer Research 21 (18), 4055-4061, 2015 | 190 | 2015 |
| Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a … SA Holstein, SH Jung, PG Richardson, CC Hofmeister, DD Hurd, ... The Lancet Haematology 4 (9), e431-e442, 2017 | 166 | 2017 |
| Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, ... Blood Cancer Journal 9 (12), 94, 2019 | 164 | 2019 |
| In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation F Pichiorri, D Palmieri, L De Luca, J Consiglio, J You, A Rocci, T Talabere, ... The Journal of experimental medicine 210 (5), 951, 2013 | 158 | 2013 |
| NCCN guidelines insights: multiple myeloma, version 3.2018 SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ... Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018 | 156 | 2018 |
| Multiple myeloma immunoglobulin lambda translocations portend poor prognosis BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, ... Nature communications 10 (1), 1911, 2019 | 146 | 2019 |
| Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, ... JCI insight 4 (11), 2019 | 143 | 2019 |
| Daratumumab in multiple myeloma AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, ... Cancer 125 (14), 2364-2382, 2019 | 142 | 2019 |
AJAY K. NOOKAAssociate Professor, Division of Bone Marrow Transplant, Winship Cancer Institute, Emory University在 emory.edu 的电子邮件经过验证
